Related Experiment Video
Updated: Jun 27, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Experimental agents which inhibit hepatocarcinogenesis
1Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea. yoonjh@snu.ac.kr
Abstract:
Hepatocellular carcinoma (HCC) is characteristically hypervascular, and therefore many antiangiogenic therapies are under clinical investigation. However, their therapeutic efficacies are still limited. While inhibition of angiogenesis results in tumor hypoxia and cell death, this may also activate a variety of hypoxia-induced cell growth and survival signals, which may promote HCC progression. Therefore, the simultaneous blockage of these signals may be essential in maximizing the efficiency of antiangiogenic therapies. Information regarding some of our experimental agents targeting these HCC signals is presented in this manuscript.
Related Concept Videos
Mutagenicity and Carcinogenicity
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Inhibition of Cdk Activity
Inhibitors of Viral Protein Synthesis
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
